


## CXCR4 antagonist 4

<b>Cat. No.:</b>	HY-144285
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>41</sub> F <sub>2</sub> N <sub>5</sub>
<b>Molecular Weight:</b>	497.67
<b>Target:</b>	CXCR; HIV
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation; Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC <sub>50</sub> =24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC <sub>50</sub> =7 nM) <sup>[1]</sup> .																																											
<b>IC<sub>50</sub> &amp; Target</b>	CXCR4 24 nM (IC <sub>50</sub> )		HIV 7 nM (IC <sub>50</sub> )																																									
<b>In Vitro</b>	<p>CXCR4 antagonist 4 (Compound 30, 0.1-10 μM, 48 hours) displays the inhibition potencies against the X4 virus in TZM-bl cells (IC<sub>50</sub>=7 nM)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="7">TZM-bl cells</td> </tr> <tr> <td>Concentration:</td> <td colspan="7">0.1, 1, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="7">48 hours</td> </tr> <tr> <td>Result:</td> <td colspan="7">Displayed inhibition potencies against the X4 virus (IC<sub>50</sub>=7 nM)</td> </tr> </table>								Cell Line:	TZM-bl cells							Concentration:	0.1, 1, 10 μM							Incubation Time:	48 hours							Result:	Displayed inhibition potencies against the X4 virus (IC <sub>50</sub> =7 nM)										
Cell Line:	TZM-bl cells																																											
Concentration:	0.1, 1, 10 μM																																											
Incubation Time:	48 hours																																											
Result:	Displayed inhibition potencies against the X4 virus (IC <sub>50</sub> =7 nM)																																											
<b>In Vivo</b>	<p>CXCR4 antagonist 4 (3, 10, 30 mg/kg) demonstrates better oral Bioavailability in a dose dependent and reached 27% for the 30 mg/kg<sup>[1]</sup>. Pharmacokinetic Parameters of CXCR4 antagonist 4 in mice<sup>[1]</sup></p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose(mg/kg)</th> <th>T<sub>1/2</sub>(h)</th> <th>C<sub>max</sub>(ng/mL)</th> <th>C<sub>12h</sub>(ng/mL)</th> <th>AUC<sub>0-8h</sub> (h*ng/mL)</th> <th>% F<sub>PO</sub> (0-8 h)</th> <th>Cl (L/h/kg)</th> <th>V<sub>d</sub> (L/kg)</th> </tr> </thead> <tbody> <tr> <td>iv</td> <td>3</td> <td>5.89</td> <td>116</td> <td></td> <td>265</td> <td></td> <td>11.3</td> <td>96.3</td> </tr> <tr> <td>po</td> <td>3</td> <td></td> <td>12.8</td> <td>1.50</td> <td>34.3</td> <td>12.9</td> <td></td> <td></td> </tr> <tr> <td>po</td> <td>10</td> <td></td> <td>54.8</td> <td>14.3</td> <td>190</td> <td>215</td> <td></td> <td></td> </tr> </tbody> </table>								Route	Dose(mg/kg)	T <sub>1/2</sub> (h)	C <sub>max</sub> (ng/mL)	C <sub>12h</sub> (ng/mL)	AUC <sub>0-8h</sub> (h*ng/mL)	% F <sub>PO</sub> (0-8 h)	Cl (L/h/kg)	V <sub>d</sub> (L/kg)	iv	3	5.89	116		265		11.3	96.3	po	3		12.8	1.50	34.3	12.9			po	10		54.8	14.3	190	215		
Route	Dose(mg/kg)	T <sub>1/2</sub> (h)	C <sub>max</sub> (ng/mL)	C <sub>12h</sub> (ng/mL)	AUC <sub>0-8h</sub> (h*ng/mL)	% F <sub>PO</sub> (0-8 h)	Cl (L/h/kg)	V <sub>d</sub> (L/kg)																																				
iv	3	5.89	116		265		11.3	96.3																																				
po	3		12.8	1.50	34.3	12.9																																						
po	10		54.8	14.3	190	215																																						

---

po	30	169	34.8	717	27.1
----	----	-----	------	-----	------

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mice <sup>[1]</sup>
Dosage:	3, 10, 30 mg/kg
Administration:	
Result:	Demonstrated better oral bioavailability in a dose dependent and reached 27% for the 30 mg/kg.

## REFERENCES

[1]. Jecs E, et al. Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. J Med Chem. 2022, 65(5):4058-4084.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA